13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001596452
Total reported value
$131.7M
$131.7M
38 檔
42.4%
At the close of Q4 2024, Sivik Global Healthcare LLC disclosed equity holdings valued at approximately $131.7M, spread across 38 reported holdings.
Sivik Global Healthcare LLC executed strategic sector rebalancing during Q4 2024, establishing 13 new positions while fully exiting 10 holdings and trimming 17 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 9.48% | — | -33.33% | |
| 2 | LLY | Eli Lilly & Co | Stock-Healthcare | 6.10% | — | +3.45% | |
| 3 | BSX | Boston Scientific CORP | Stock-Healthcare | 5.17% | — | +4.76% | |
| 4 | MCK | Mckesson CORP | Stock-Healthcare | 4.50% | — | -25.00% | |
| 5 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 4.12% | — | -14.29% | |
| 6 | SYK | Stryker CORP | Stock-Healthcare | 3.79% | — | -25.93% | |
| 7 | THC | Tenet Healthcare CORP | Stock-Healthcare | 3.66% | — | -15.38% | |
| 8 | UHS | Universal Health Services-b | Stock-Healthcare | 3.54% | — | -16.67% | |
| 9 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 3.33% | — | — | |
| 10 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 3.17% | — | -22.22% | |
| 11 | HCA | Hca Healthcare Inc | Stock-Healthcare | 3.16% | — | — | |
| 12 | CAH | Cardinal Health Inc | Stock-Healthcare | 3.11% | — | +11.11% | |
| 13 | DHR | Danaher CORP | Stock-Healthcare | 3.02% | — | -16.67% | |
| 14 | ABT | Abbott Laboratories | Stock-Healthcare | 2.98% | — | -16.67% | |
| 15 | COR | Cencora Inc | Stock-Healthcare | 2.96% | — | — | |
| 16 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 2.76% | — | +30.00% | |
| 17 | WAT | Waters CORP | Stock-Healthcare | 2.74% | — | — | |
| 18 | HUM | Humana Inc | Stock-Healthcare | 2.67% | — | +100.00% | |
| 19 | A | Agilent Technologies Inc | Stock-Healthcare | 2.48% | — | — | |
| 20 | ABBV | Abbvie Inc | Stock-Healthcare | 2.34% | — | — | |
| 21 | SGRY | Surgery Partners Inc | Stock-Other | 2.23% | — | -13.04% | |
| 22 | AVTR | Avantor Inc | Stock-Healthcare | 2.22% | — | -20.00% | |
| 23 | EHC | Encompass Health CORP | Stock-Healthcare | 2.19% | — | -10.00% | |
| 24 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 2.08% | — | — | |
| 25 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.95% | — | — | |
| 26 | CI | THE Cigna Group | Stock-Healthcare | 1.75% | — | — | |
| 27 | BIO | Bio-rad Laboratories-a | Stock-Healthcare | 1.73% | — | — | |
| 28 | SNN | Smith & Nephew PLC -spon Adr | Stock-Other | 1.62% | — | -10.71% | |
| 29 | SEM | Select Medical Holdings CORP | Stock-Other | 1.49% | — | +7.14% | |
| 30 | ZTS | Zoetis Inc | Stock-Healthcare | 1.29% | — | — | |
| 31 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 1.11% | — | -50.00% | |
| 32 | ACHC | Acadia Healthcare Co Inc | Stock-Other | 1.04% | — | -56.52% | |
| 33 | BNTX | Biontech Se-adr | Stock-Other | 0.90% | — | — | |
| 34 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 0.87% | — | — | |
| 35 | RGEN | Repligen CORP | Stock-Healthcare | 0.76% | — | -60.00% | |
| 36 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.65% | — | — | |
| 37 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.64% | — | — | |
| 38 | MRVI | Maravai Lifesciences Hldgs-a | Stock-Other | 0.40% | — | -67.06% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | UNH | Unitedhealth Group Inc | +3.3% | NEW | New buy |
| 2 | WAT | Waters CORP | +2.7% | NEW | New buy |
| 3 | A | Agilent Technologies Inc | +2.5% | NEW | New buy |
| 4 | ABBV | Abbvie Inc | +2.3% | NEW | New buy |
| 5 | BMY | Bristol-myers Squibb Co | +2.1% | NEW | New buy |
| 6 | EW | Edwards Lifesciences CORP | +2% | NEW | New buy |
| 7 | CI | THE Cigna Group | +1.8% | NEW | New buy |
| 8 | BIO | Bio-rad Laboratories-a | +1.7% | NEW | New buy |
| 9 | BSX | Boston Scientific CORP | +1.4% | +4.76% | Add |
| 10 | HUM | Humana Inc | +1.3% | +100.00% | Add |
| 11 | ZTS | Zoetis Inc | +1.3% | NEW | New buy |
| 12 | CAH | Cardinal Health Inc | +1% | +11.11% | Add |
| 13 | BNTX | Biontech Se-adr | +0.9% | NEW | New buy |
| 14 | ALNY | Alnylam Pharmaceuticals Inc | +0.9% | NEW | New buy |
| 15 | VRTX | Vertex Pharmaceuticals Inc | +0.8% | +30.00% | Add |
| 16 | LLY | Eli Lilly & Co | +0.7% | +3.45% | Add |
| 17 | MDGL | Madrigal Pharmaceuticals Inc | +0.7% | NEW | New buy |
| 18 | SRPT | Sarepta Therapeutics Inc | +0.6% | NEW | New buy |
| 19 | COR | Cencora Inc | +0.6% | — | Unchanged |
| 20 | ISRG | Intuitive Surgical Inc | +0.5% | -14.29% | Trim |
| 21 | MCK | Mckesson CORP | +0.3% | -25.00% | Trim |
| 22 | EHC | Encompass Health CORP | +0.1% | -10.00% | Trim |
| 23 | ABT | Abbott Laboratories | +0.1% | -16.67% | Trim |
| 24 | SNN | Smith & Nephew PLC -spon Adr | -0.2% | -10.71% | Trim |
| 25 | HCA | Hca Healthcare Inc | -0.3% | — | Unchanged |
| 26 | ✓ | Put - Spy 100 @ 553 Exp 10/31/2024 | -0.3% | EXIT | Sold out |
| 27 | SYK | Stryker CORP | -0.3% | -25.93% | Trim |
| 28 | ✓ | Put - Spy 100 @ 565 Exp 10/31/2024 | -0.4% | EXIT | Sold out |
| 29 | DHR | Danaher CORP | -0.5% | -16.67% | Trim |
| 30 | AVTR | Avantor Inc | -0.5% | -20.00% | Trim |
| 31 | SEM | Select Medical Holdings CORP | -0.6% | +7.14% | Add |
| 32 | ASND | Ascendis Pharma A/S | -0.6% | EXIT | Sold out |
| 33 | ZBH | Zimmer Biomet Holdings Inc | -0.7% | -50.00% | Trim |
| 34 | UHS | Universal Health Services-b | -0.8% | -16.67% | Trim |
| 35 | RGEN | Repligen CORP | -0.8% | -60.00% | Trim |
| 36 | THC | Tenet Healthcare CORP | -0.9% | -15.38% | Trim |
| 37 | SGRY | Surgery Partners Inc | -0.9% | -13.04% | Trim |
| 38 | MRVI | Maravai Lifesciences Hldgs-a | -1.1% | -67.06% | Trim |
| 39 | STVN | Stevanato Group S.p.A. | -1.2% | EXIT | Sold out |
| 40 | TEVA | Teva Pharmaceutical-sp Adr | -1.3% | EXIT | Sold out |
| 41 | NVO | Novo-nordisk A/s-spons Adr | -1.4% | -22.22% | Trim |
| 42 | ACHC | Acadia Healthcare Co Inc | -2.1% | -56.52% | Trim |
| 43 | RVTY | Revvity Inc | -2.2% | EXIT | Sold out |
| 44 | WST | West Pharmaceutical Services | -2.2% | EXIT | Sold out |
| 45 | MDT | Medtronic plc | -2.3% | EXIT | Sold out |
| 46 | BAX | Baxter International Inc | -2.4% | EXIT | Sold out |
| 47 | BDX | Becton Dickinson And Co | -2.6% | EXIT | Sold out |
| 48 | XBI | Ss Spdr S&p Biotech ETF | -3.1% | -33.33% | Trim |
According to official SEC Form 13F filings, Sivik Global Healthcare LLC reported a total U.S. public equity portfolio value of $131.7M across 38 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including XBI, LLY, BSX) accounted for 42.4% of total reported equity market value during Q4 2024.
Top New Position Initiated
UNH
市值: $6.3M
Top Position Liquidated / Trimmed
BDX
前期市值: $6.0M
During Q4 2024, Sivik Global Healthcare LLC's top holdings by market value included XBI (9.5%)、LLY (6.1%)、BSX (5.2%). The largest single position, XBI, represented 9.5% of total portfolio value.
In Q4 2024, Sivik Global Healthcare LLC made 46 total portfolio adjustments, initiating 13 new buys, adding to 6 positions, trimming 17 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.